Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Stage/Subtype:  recurrent renal cell cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 61 for your search:
Start Over
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CA209-374, NCI-2016-00405, 2015-003286-28, NCT02596035
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AV-951-15-303, NCI-2016-00282, NCT02627963
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Stereotactic Radiosurgery in Treating Patients with Kidney Tumors Who Are Poor Candidates for Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 12806, NCI-2010-01064, NCT00458484
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-04, NCI-2015-00740, NCT02386111
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1128-CA, NCI-2016-00449, NCT02599324
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7080-A001-111, NCI-2016-00529, NCT02501096
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: X4P-001-RCCA, NCI-2016-00531, NCT02667886
An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCAGN 1876-101, NCI-2016-01221, NCT02697591
Anti-CD70 Peripheral Blood Lymphocytes in Treating Patients with CD70 Expressing Solid Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 16-C-0131, NCI-2016-01030, NCT02830724
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX014-01, NCI-2016-01448, NCT02837991
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, 0108M06725, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Tumor Infiltrating Lymphocytes and Aldesleukin after Chemotherapy and Pembrolizumab in Treating Patients with Metastatic Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0166, NCI-2013-01461, 100166, P09567, 306343, NCT01174121
Everolimus and Bevacizumab in Treating Patients with Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-226, NCI-2011-01944, NCT01399918
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1152, NCI-2012-02027, NCT01767636
Capmatinib in Treating Patients with Papillary Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0037, NCI-2014-02464, 140037, 340263, 09-25-0099, P131324, NCT02019693
Personalized Dose of Axitinib in Treating Patients with Previously Treated Local Recurrent or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE7815, NCI-2016-00020, IRB# 15-1386, 15-1386, NCT02579811
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AGS-16C3F-15-3, NCI-2016-00404, NCT02639182
Nanoparticle Albumin-Bound Rapamycin in Treating Patients with Advanced Cancer with mTOR Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1313, NCI-2015-02151, NCT02646319
Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients with Locally Advanced or Metastatic Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: S1500, NCI-2015-01707, NCT02761057
Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 2 to 30
Trial IDs: ADVL1622, NCI-2016-01258, NCT02867592
Start Over